Can a Genomic Test — Spare You Chemotherapy?
For some early breast cancers, a laboratory test on your tumour tissue can predict whether chemotherapy is likely to add benefit over hormone therapy alone. This test exists, is available in India, and is poorly known — many eligible patients never hear about it.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026
- A validated clinical tool — Genomic recurrence-score tests are supported by large international trials and recommended in ASCO and ESMO guidance for eligible patients.
- Not for every breast cancer — It applies specifically to early-stage, hormone receptor-positive, HER2-negative cancer — a common but specific subtype.
- Can spare some patients chemotherapy — In a proportion of patients, the result supports skipping chemotherapy entirely and continuing with hormone therapy alone.
- Available in India — Your existing tissue block is sent to an accredited laboratory abroad. Results typically return within two to three weeks.
on Panel
Survival Rate*
Treated
(800+ reviews)
For early-stage, hormone receptor-positive, HER2-negative breast cancer, a genomic recurrence-score test can predict whether chemotherapy is likely to add meaningful benefit beyond hormone therapy. ASCO and ESMO guidance supports using these results to guide the chemotherapy decision. Tissue is sent to a laboratory and results come back within two to three weeks.
Which genomic tests are used and how do they differ?
| Feature | Oncotype DX | MammaPrint | Prosigna (PAM50) |
|---|---|---|---|
| Genes analysed | 21 genes | 70 genes | 50 genes |
| Cancer type | HR+, HER2−, early stage | HR+, HER2−, early stage | HR+, HER2−, postmenopausal |
| Result format | Score 0–100 (low, intermediate, or high risk) | Binary: low risk or high risk | Risk category with 10-year distant recurrence estimate |
| Key trial evidence | TAILORx and RxPONDER (ASCO-cited) | MINDACT trial (ESMO-cited) | TransATAC and ABCSG-8 studies |
| Where tissue is tested | US laboratory (Genomic Health) | Netherlands or US (Agendia) | Can be run on local validated equipment |
| Access in India | Available — tissue sent abroad | Available — tissue sent abroad | Access varies by centre |
Which patients does the test actually apply to?
The test is designed for a specific clinical situation: early-stage breast cancer (Stage I or II) that is hormone receptor-positive and HER2-negative, where your oncologist is weighing whether to add chemotherapy to hormone therapy.
It is not used for triple-negative breast cancer, HER2-positive cancer, or metastatic disease. The question it answers is narrow: for your particular tumour biology, does chemotherapy add enough benefit to justify its costs and side effects?
The RxPONDER trial, cited by ASCO, extended this to postmenopausal patients with one to three positive lymph nodes. If that describes your situation, ask your oncologist whether genomic testing applies to you.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Am I a candidate for this test?
- Your breast cancer is Stage I or II — early, not spread to distant organs
- Your biopsy showed hormone receptor-positive results (ER+ or PR+)
- Your biopsy showed HER2-negative results
- Your oncologist is considering adding chemotherapy to hormone therapy
- You have had surgery and tumour tissue is stored at the pathology laboratory
- You have not yet started chemotherapy
Are these tests available in India and what do they cost?
Both Oncotype DX and MammaPrint are accessible in India. Your tumour tissue block — already stored at the pathology laboratory from your surgery or biopsy — is sent to an accredited laboratory abroad. You do not need a repeat procedure.
The cost is significant. It is a one-time test, and for patients whose result supports avoiding chemotherapy, it may avoid months of treatment cost and side effects. Ask your oncologist or the hospital billing team for a current figure; costs vary by centre and have changed over time.
Some Indian health insurers and corporate health plans now cover genomic testing. Ask your insurer before the sample is sent, and request a pre-authorisation letter if they agree to cover it.
Questions families ask most
What does an intermediate score mean?
The TAILORx trial found that postmenopausal women with an intermediate recurrence score did not benefit significantly from adding chemotherapy to hormone therapy. For premenopausal women, some intermediate scores did show a benefit — the result is more nuanced. Your oncologist will interpret the number in the context of your age, menopausal status, and other tumour features. An intermediate score is not a failed test. It narrows the decision to a clinical conversation where your specific circumstances matter most.
A low score means the cancer won't come back, doesn't it?
No, and this is an important distinction. A low score means chemotherapy is unlikely to add meaningful benefit beyond hormone therapy for your tumour type. It does not mean the cancer cannot return. You still need hormone therapy and regular follow-up. What the score tells you is that adding chemotherapy would carry its real side effects without a proportionate benefit for your specific tumour biology — not that you are free of all risk.
Is this the same as BRCA testing or genetic testing?
No. Genomic recurrence-score testing analyses gene activity inside your tumour cells to predict how the cancer is likely to behave and whether it will respond to chemotherapy. It is a test of the tumour. BRCA and hereditary cancer gene tests analyse your own DNA — from a blood or saliva sample — to identify inherited variants that raise your lifetime risk of cancer. Both are valid and answer different questions. Having one done does not mean the other is irrelevant to you.
My oncologist has not mentioned this test. Should I ask?
Yes. If your diagnosis fits — early-stage, hormone receptor-positive, HER2-negative breast cancer and chemotherapy is being discussed — ask directly: 'Is a genomic recurrence-score test like Oncotype DX or MammaPrint applicable for my case?' Your oncologist will tell you whether it applies and, if not, why. Awareness and ordering pathways for these tests vary across India, and not every centre routinely raises them. Asking is how eligible patients learn the option exists.
What if I cannot afford the test?
This is a real barrier for many patients in India, and a few options are worth exploring before concluding it is out of reach. Ask your insurer whether genomic testing is covered — the landscape is changing and some plans now include it. Ask the hospital billing team whether a payment plan or institutional arrangement is available. Discuss with your oncologist whether your pathology report alone provides enough information to guide the chemotherapy decision. For some patients, the clinical picture without genomic testing leads to the same conclusion.
Does the test still apply if I have lymph node involvement?
For patients with one to three positive lymph nodes, ASCO guidance supports using Oncotype DX in guiding the chemotherapy decision. The RxPONDER trial specifically showed that postmenopausal women with one to three positive nodes and a low score did not benefit from adding chemotherapy. For premenopausal women with node involvement, the evidence is more complex. For patients with four or more positive nodes, chemotherapy is generally recommended regardless of the genomic score. Ask your oncologist which of these categories your lymph node status puts you in.
Explore 95 more Understanding Chemotherapy, Myths & Trials topics
Does Chemotherapy Work? Realistic Expectations
- Can Chemotherapy Be Avoided With a Genomic Test?
- Can Chemotherapy Cure Cancer?
- Can You Stop Chemotherapy Midway?
- Chemotherapy When You Are Already Very Unwell
- Chemotherapy or Surgery First: How Is It Decided?
- Do Worse Side Effects Mean It Is Working Better?
- Does Chemotherapy Actually Work?
- Does Everyone React the Same Way to Chemotherapy?
- Getting Palliative Care Alongside Chemotherapy
- How Will I Know It Is Working?
- Is Chemotherapy Worth the Side Effects?
- Is Palliative Chemotherapy Worth Having?
- Is There an Alternative to Chemotherapy?
- Reduced-Dose Chemotherapy: When Is It Offered?
- What Does Palliative Chemotherapy Mean?
- What If Chemotherapy Does Not Work?
HUB — Chemotherapy Myths and Alternative Treatment Claims
HUB — What Is Chemotherapy and Why Has It Been Advised?
Is This Chemotherapy? Hormone and Targeted Therapy
- Are EGFR Tablets Like Gefitinib Chemotherapy?
- Are Steroids Chemotherapy?
- Chemotherapy vs Hormone Therapy
- Chemotherapy vs Immunotherapy
- Chemotherapy vs Targeted Therapy
- Do You Lose Your Hair on Every Cancer Medicine?
- Is Capecitabine Chemotherapy? Yes, and Why It Matters
- Is Every Cancer Medicine Chemotherapy?
- Is Imatinib Chemotherapy?
- Is Letrozole or Anastrozole Chemotherapy?
- Is Tamoxifen Chemotherapy?
- Which Precautions Apply to Which Treatment?
Myths & Alternative Treatment Claims
- Can Ayurveda Treat Cancer Instead of Chemotherapy?
- Can You Use Traditional Medicine Alongside Chemotherapy?
- Cannabis Oil and Cancer Treatment Claims
- Chemotherapy Myths in Telugu Households
- Do Cow Urine, Wheatgrass and Home Remedies Treat Cancer?
- Does Chemotherapy Kill You? The Evidence
- Homeopathy and Cancer Treatment Claims
- How to Spot a Fake Cancer Cure
- Is Chemotherapy Worse Than the Cancer?
- Myth: Chemotherapy Destroys Your Immunity Forever
- Myth: Chemotherapy Is Contagious or Dangerous to Others
- Myth: Chemotherapy Is Just a Money-Making Business
- Myth: Chemotherapy Means the Cancer Is Terminal
- Myth: Chemotherapy Patients Must Be Isolated
- Myth: Chemotherapy Spreads Cancer or Causes New Cancers
- Myth: Everyone Loses All Their Hair
- Myth: Once You Start Chemotherapy You Cannot Stop
- Myth: You Cannot Eat Anything During Chemotherapy
- Naturopathy, Detox and Alkaline Diet Claims
- Talking to a Family Member Who Refuses Chemotherapy
- What Happens If You Refuse Chemotherapy?
- Why Do People Believe Chemotherapy Does Not Work?
Types & Classes of Chemotherapy
- Alkylating Agent Chemotherapy: What to Expect
- Anthracycline Chemotherapy: What to Expect
- Antimetabolite Chemotherapy: What to Expect
- Biosimilars in Cancer Treatment
- Can Your Chemotherapy Be Changed Partway Through?
- Generic vs Innovator Chemotherapy Drugs
- Growth Factor Injections After Chemotherapy
- Platinum-Based Chemotherapy: What to Expect
- Single-Agent vs Combination Chemotherapy
- Supportive Medicines Given With Chemotherapy
- Taxane Chemotherapy: What to Expect
- Topoisomerase Inhibitor Chemotherapy: What to Expect
- Types of Chemotherapy: The Main Classes Explained
- Vinca Alkaloid Chemotherapy: What to Expect
- What Is Dose-Dense Chemotherapy?
- What Is Metronomic Chemotherapy?
- What Is a Chemotherapy Regimen?
- Why Am I Given Steroids With Chemotherapy?
- Why the Class of Chemotherapy Decides Your Side Effects
Understanding Chemotherapy & Why It Is Advised
- Can Chemotherapy Be Refused or Delayed?
- Can I Get a Second Opinion Before Starting?
- Chemotherapy After Surgery: Why It Is Needed
- Chemotherapy Before Surgery: Why It Is Given First
- Chemotherapy Terminology: A Plain-English Glossary
- Chemotherapy for a Cancer That Has Come Back
- Chemotherapy in a Clinical Trial
- Chemotherapy vs Targeted Therapy vs Immunotherapy
- Consent for Chemotherapy: What You Are Signing
- Curative, Adjuvant, Neoadjuvant and Palliative: What Your Intent Means
- Does Chemotherapy Mean My Cancer Is Advanced?
- How Long Does a Course of Chemotherapy Last?
- How Many Cycles of Chemotherapy Will I Need?
- Is Chemotherapy Painful?
- Questions to Ask Before Starting Chemotherapy
- What Chemotherapy Cannot Do
- What Happens Inside Your Body During Chemotherapy?
- What Is Chemoradiation?
- What Is Chemotherapy and How Does It Work?
- What Is Maintenance Chemotherapy?
- Who Decides Your Chemotherapy Plan?
- Why Has Chemotherapy Been Advised for Me?
- Why Is Chemotherapy Given in Cycles?
- Your Chemotherapy Plan Sheet: How to Read It
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Frequently asked questions
Can a genomic test completely replace my oncologist's judgment on chemotherapy?
No. The test reduces uncertainty about tumour biology, but it is one input into the decision, not the decision itself. Your oncologist uses the score alongside your age, menopausal status, lymph node involvement, fitness, and your own preferences. What the result does is make the conversation more specific and the recommendation more tailored to your tumour. The final decision is always a clinical one, and your oncologist is the right person to interpret what your score means for you.
What happens to my tissue and how long does it take?
Your tissue block — the preserved tumour sample already stored at the pathology laboratory from your surgery — is sent to the testing laboratory. You do not need a new biopsy or procedure. Results typically return within two to three weeks from when the sample is received. Ask your care team when the sample is being dispatched so you have a realistic timeline, rather than waiting without a reference point.
Will health insurance in India cover this test?
Coverage varies. A growing number of Indian insurers and corporate health plans have begun covering genomic tests for breast cancer, but many have not. The most useful step is to call your insurer before the sample is sent and ask specifically whether Oncotype DX or MammaPrint is covered under your policy. Request a pre-authorisation letter if they agree. If your plan does not cover it, discuss with your oncologist whether the clinical information already available can guide the decision.
My cancer is triple-negative. Does this test apply to me?
No. These tests are designed for hormone receptor-positive, HER2-negative breast cancer. Triple-negative cancer does not respond to hormone therapy, so the question the test is answering does not apply to it. For triple-negative breast cancer, chemotherapy is a standard part of the treatment approach, and your oncologist will explain what that means for your specific situation.
If the result is low risk, what treatment do I have instead of chemotherapy?
Hormone therapy — typically a daily tablet taken for five to ten years. The most common forms are tamoxifen and aromatase inhibitors, which work by reducing oestrogen's effect on the cancer cells. A low genomic score means the evidence supports hormone therapy alone for your tumour type without adding chemotherapy. You may also be offered ovarian suppression depending on your age and menopausal status. Your oncologist will outline the full plan.
Can this test be done if I had chemotherapy before surgery?
Generally no. The test is designed to guide a decision about whether to give chemotherapy, which means it needs to be done before chemotherapy has started. If you had neoadjuvant chemotherapy — given before surgery — the decision has already been made and the test is no longer applicable in the same way. Discuss your specific treatment sequence with your oncologist if you are unsure where you stand.
Chemotherapy Topics
Browse our complete chemotherapy guide — 1133 pages on side effects, medicines, cost, daily life and care in Hyderabad. Tap any topic to read more.